As previously reported, Barclays analyst James Gordon downgraded GSK (GSK) to Underweight from Equal Weight with a 1,780 GBp price target as the firm transferred coverage of European large-cap pharma to a new analyst. The firm cites limited pipeline readouts, which it also see carrying risk, as well as the new CEO’s “limited room” to maneuver for the downgrade.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK downgraded to Underweight from Equal Weight at Barclays
- GSK announces approval of Exdensur by Japan’s MHLW
- Kennedy scales back number of vaccines recommended for children, NYT says
- GSK announces China’s NMPA approved Nucala as add-on maintenance treatment
- Trump Weekly: Furniture tariffs delayed, drugmakers hike prices